drugset
drugset / Trial / NCT05123079

Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants

NCT05123079 ↗

Phase 1 Completed 12 enrolled Cerevel Therapeutics, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, single-center trial in healthy participants. This is a crossover design, open-label treatment trial with 3 periods, 6 sequences.

Timeline

Start
2021-11-02
Primary completion
2021-11-21
Completion
2021-12-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Darigabat Small molecule 25 mg Oral

Indications

No indication recorded.